Publications by authors named "James R Bosscher"
Gynecol Oncol
December 2009
Article Synopsis
- New agents are needed for uterine leiomyosarcoma patients who no longer respond to existing treatments, and sunitinib was tested for its effectiveness and toxicity in these cases.
- In a study involving 25 patients, only 2 showed a partial tumor response and 4 were progression-free for at least 6 months, indicating limited efficacy.
- The treatment had notable side effects, including various grades of neutropenia, anemia, and fatigue, while the median progression-free survival was only 1.5 months, demonstrating that sunitinib is not a viable option for this patient group.
